1. Introduction {#sec1-pharmaceutics-11-00042}
===============

Non-invasive imaging of living tissue is of great importance in the medical field. The magnetic resonance imaging (MRI) method is one of the most frequently used and important imaging techniques in clinical medicine. In fact, the use of MRI contrast agents plays a crucial role in accurately evaluating physiological and pathological changes. The majority of MRI contrast agents approved by the US Food and Drug Administration (FDA) are gadolinium-based contrast agents (GBCAs) such as Magnevist (a Gd^III^ complex agent) \[[@B1-pharmaceutics-11-00042],[@B2-pharmaceutics-11-00042],[@B3-pharmaceutics-11-00042]\]. Although they are used on a daily basis, this modality still faces many challenges \[[@B4-pharmaceutics-11-00042],[@B5-pharmaceutics-11-00042],[@B6-pharmaceutics-11-00042],[@B7-pharmaceutics-11-00042],[@B8-pharmaceutics-11-00042]\]. For example, people with moderate to advanced kidney failure are in danger of developing nephrogenic systemic fibrosis through the use of GBCAs. Thus, it is urgently required to exploit novel agents that exhibit adequate contrast enhancement with a very low risk.

Metal-free magnetic nanoparticles containing nitroxide radicals as a spin source have attracted great interest since the 1980s \[[@B9-pharmaceutics-11-00042]\] because of their lack of toxicity, despite the imaging ability being less compared to Gd^III^ complex agents \[[@B10-pharmaceutics-11-00042]\] and their having less reduction resistance to antioxidants such as ascorbic acid and glutathione \[[@B11-pharmaceutics-11-00042]\]. However, the reduction resistance should potentially improve through the molecular design and/or the micelle construction of nitroxide radicals \[[@B12-pharmaceutics-11-00042],[@B13-pharmaceutics-11-00042],[@B14-pharmaceutics-11-00042],[@B15-pharmaceutics-11-00042],[@B16-pharmaceutics-11-00042],[@B17-pharmaceutics-11-00042]\]. In this context, we have recently prepared metal-free magnetic mixed micelles comprised of a surfactant, Brij 58 (**1**) or Tweens 80 (**2**), and pyrrolidine-*N*-oxyl radical **3**, namely **1**/**3** or **2**/**3** ([Figure 1](#pharmaceutics-11-00042-f001){ref-type="fig"}), according to a simple experimental procedure \[[@B18-pharmaceutics-11-00042],[@B19-pharmaceutics-11-00042]\]. These micelles showed high colloidal stability, reduction resistance to ascorbic acid, and contrast enhancement in the *T*~1~-weighted MRI in phosphate-buffered saline (PBS) in vitro and in vivo. The mixed micelle **2**/**3** was found to be much less toxic than **1**/**3**. Furthermore, additional hydrophobic fluorophores or drugs were stably encapsulated inside the mixed micelles. Although passive targeting can be expected due to the micelle size (10--20 nm), the micelles that we prepared did not possess any active targeting site for tumor.

Herein, we report on the novel metal-free mixed micelles including nitroxide radicals **4**~n~ conjugated with a [d]{.smallcaps}-glucosamine unit as a tumor targeting site, because [d]{.smallcaps}-glucosamine derivatives are well-known to accumulate in tumor cells \[[@B20-pharmaceutics-11-00042],[@B21-pharmaceutics-11-00042],[@B22-pharmaceutics-11-00042],[@B23-pharmaceutics-11-00042]\]. The obtained magnetic mixed micelles showed little toxicity, excellent in vitro MRI contrast ability, and high stability in the presence of an excess amount of ascorbic acid. When applied to in vivo imaging for healthy mice, bright MRI contrast enhancement was observed in the liver.

2. Results and Discussion {#sec2-pharmaceutics-11-00042}
=========================

2.1. Preparation, Stability and In Vitro MRI Contrast Ability of ***2**/**4**~n~* {#sec2dot1-pharmaceutics-11-00042}
---------------------------------------------------------------------------------

The nitroxide radicals **4**~n~ (*n* = 14, 16, and 18 in [Figure 1](#pharmaceutics-11-00042-f001){ref-type="fig"}, [Figures S1 and S2](#app1-pharmaceutics-11-00042){ref-type="app"}) were synthesized by condensation of the racemic benzoic acid derivatives of the nitroxide radicals (a 1:1 mixture of (*R*,*R*) and (*S*,*S*) enantiomers) \[[@B24-pharmaceutics-11-00042],[@B25-pharmaceutics-11-00042]\] and [d]{.smallcaps}-tetraacetylglucosamine \[[@B26-pharmaceutics-11-00042],[@B27-pharmaceutics-11-00042],[@B28-pharmaceutics-11-00042]\], followed by deacetylation ([Schemes S1 and S2 in the Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"}).

The mixed micelles **2**/**4**~n~ ([Figure 1](#pharmaceutics-11-00042-f001){ref-type="fig"}) were prepared at a concentration of 10 mM for each component in the PBS according to the procedure described in the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"}. The stability of the micelles was found to depend on the length of the alkyl chain (*n* = 14, 16, and 18) in the radicals **4**~n~ ([Table 1](#pharmaceutics-11-00042-t001){ref-type="table"} and [Figure 2](#pharmaceutics-11-00042-f002){ref-type="fig"}). The **2**/**4**~16~ and **2**/**4**~18~ were formed as a clear dispersion immediately after preparation and their mean diameter gradually increased up to 92 and 45 nm after one week, respectively ([Table 1](#pharmaceutics-11-00042-t001){ref-type="table"}). The micelle **2**/**4**~14~ collapsed within one day to give white precipitates of **4**~14~ after 24 h. From these results, summarized in [Table 1](#pharmaceutics-11-00042-t001){ref-type="table"}, the relative stability of the micelles **2**/**4**~n~ in PBS was in the following order: **2**/**4**~18~ \> **2**/**4**~16~ \> **2**/**4**~14~. The similar dependence of the micellar stability on the alkyl chain length in the nitroxide radicals **4**~n~ was also observed in the cases of the mixed micelles **1**/**3** and **2**/**3** \[[@B18-pharmaceutics-11-00042],[@B19-pharmaceutics-11-00042]\]. The mean diameters of the resulting magnetic mixed micelles **2**/**4**~n~ in PBS were determined to be 13 to 16 nm by DLS analysis ([Table 1](#pharmaceutics-11-00042-t001){ref-type="table"} and [Figure 2](#pharmaceutics-11-00042-f002){ref-type="fig"}). Their mean diameters fell in a range of 10--100 nm, which is required for the most prolonged blood circulation time.

Importantly, the once-precipitated sample of **2**/**4**~14~ was revived to the original clear dispersion with the same diameter (16 nm) by just heating it with full reproducibility ([Table 1](#pharmaceutics-11-00042-t001){ref-type="table"}). The micelle **2**/**4**~14~ turned out to be easily available as a clear dispersion even after the long-term preservation of the precipitated sample.

The dependence of the alkyl chain length in **4**~n~ on the longitudinal relaxivity (*r*~1~) of **2**/**4**~n~ was determined from the relaxation time (*T*~1~) as a function of the concentration at 25 °C by using an MRI machine at 7.0 T. Sufficiently bright *T*~1~-weighted MR phantom images were obtained at a concentration of 10 mM of the magnetic mixed micelles **2**/**4**~14~, **2**/**4**~16~, and **2**/**4**~18~ as compared with that of the control PBS (panel A, E, and I in [Figure 3](#pharmaceutics-11-00042-f003){ref-type="fig"}a). This result implies that **2**/**4**~n~ may show a distinct MRI contrast enhancement in vivo in this concentration or higher. The linear regression analysis yielded *r*~1~ = 0.14, 0.13, and 0.11 mM^−1^s^−1^ for **2**/**4**~14~, **2**/**4**~16~ and **2**/**4**~18~, respectively ([Figure 3](#pharmaceutics-11-00042-f003){ref-type="fig"}b). That is, the MRI contrast ability of the micelle **2**/**4**~n~ in PBS was in the following order: **2**/**4**~14~ \> **2**/**4**~16~ \> **2**/**4**~18~. The mixed micelle **2**/**4**~14~ was used for further experiments for the following two reasons: (1) **2**/**4**~14~ exhibited superior in vitro MRI-enhanced ability to those of **2**/**4**~16~ and **2**/**4**~18~, and (2) the clear dispersion was fully revived in a reproducible manner by simply heating the precipitated sample. Although the stability of the **2**/**4**~14~ was less than that of **2**/**4**~16~ and **2**/**4**~18~ as mentioned above ([Table 1](#pharmaceutics-11-00042-t001){ref-type="table"}), we gave priority to the MRI-enhanced ability over the stability.

These *r*~1~ values were much larger than those of micelles **2**/**3** and **1**/**3** (*r*~1~ = 0.07, and 0.09 mM^−1^s^−1^, respectively, at 7.0 T), which we reported previously, although they were much lower than those of Gd^III^ complex agents \[[@B6-pharmaceutics-11-00042]\]. These experimental results could be interpreted in terms of the slower rotation diffusion of **4**~14~ than that of **3** inside the mixed micelles \[[@B29-pharmaceutics-11-00042],[@B30-pharmaceutics-11-00042],[@B31-pharmaceutics-11-00042]\]. In order to compare the rotation diffusion mobility between radicals **4**~14~ and **3** inside the micelles, the electron paramagnetic resonance (EPR) spectra of radical **4**~14~ or **3** in the micelles consisting of a 1:0.01 molar ratio of surfactant **2** and **4**~14~ or **3** were measured in the temperature range 263--298 K and then were numerically simulated as described in the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"} ([Figure 4](#pharmaceutics-11-00042-f004){ref-type="fig"} and [Figure S3](#app1-pharmaceutics-11-00042){ref-type="app"}, and [Table S1](#app1-pharmaceutics-11-00042){ref-type="app"}). The temperature dependence of the rotation diffusion mobility was successfully described by Arrhenius law with the values of activation energy (*E^a^~z~*) shown in [Table 2](#pharmaceutics-11-00042-t002){ref-type="table"}, indicating that **4**~14~ showed slower rotational diffusion inside the micelle to produce a highly enhanced MRI compared to **3**. The better *r*~1~ of **2**/**4**~14~ than **2**/**4**~16~ and **2**/**4**~18~ mentioned above might be interpreted by the slower rotation diffusion mobility of **4**~14~ than **4**~16~ and **4**~18~.

2.2. Reduction Resistivity of ***2**/**4**~14~* in the Presence of Ascorbic Acid {#sec2dot2-pharmaceutics-11-00042}
--------------------------------------------------------------------------------

The concentration of ascorbic acid in the healthy adult serum was reported to be kept in the range of 14.9--52.8 μM by a daily intake of ascorbic acid (60 mg) \[[@B32-pharmaceutics-11-00042]\]. When nitroxide radicals were applied to the in vivo MRI measurement, radical reduction occurred and resulted in a significant decrease in the MRI contrast \[[@B33-pharmaceutics-11-00042],[@B34-pharmaceutics-11-00042],[@B35-pharmaceutics-11-00042]\]. For example, 2,2,6,6-tetramethylpiperidine-*N*-oxyl (TEMPO) derivatives, such as 4-oxo-2,2,6,6-tetramethylpiperidine-*N*-oxyl (TEMPONE) and 4-hydroxy-2,2,6,6-tetramethylpiperidine-*N*-oxyl (TEMPOL), were reduced rapidly (half-life (*τ*~1/2~) \< 2 min) to the corresponding hydroxylamines in the presence of ascorbic acid \[[@B36-pharmaceutics-11-00042]\]. In our molecular design, we expected that the interplay between four long hydrophilic tails in **2** and four neighboring substituents in **4**~14~ should enhance the reduction resistance to ascorbic acid sterically. The decay of **4**~14~ in **2**/**4**~14~ in response to a large excess of ascorbic acid (20 equiv based on **4**~14~) in PBS was monitored by EPR spectroscopy ([Figure 5](#pharmaceutics-11-00042-f005){ref-type="fig"}). As expected, the *τ*~1/2~ of **2/4**~14~ (30 min) was almost comparable to that of **2**/**3** (33 min) and much longer than that of **1**/**3** (7 min) \[[@B19-pharmaceutics-11-00042]\].

2.3. Biomedical Application of ***2**/**4**~14~* {#sec2dot3-pharmaceutics-11-00042}
------------------------------------------------

Since biocompatibility is a prerequisite of using the magnetic mixed micelles as an MRI contrast agent, the cancer cell viability of **2**/**4**~14~ was assessed by the CCK-8 assay at the initial concentration of 2.5 mM for **2** and **4**~14~ and compared with those of pure micelle of **2**, designated as **P2**, ([Figure 6](#pharmaceutics-11-00042-f006){ref-type="fig"}a). Both **P2** and **2**/**4**~14~ exhibited little cytotoxicity to HeLa cells at concentrations up to 2.5 mM, demonstrating that **2**/**4**~14~ is an appropriate candidate for in vivo experiment. In addition, the body weights gradually increased in the healthy Institute of Cancer Research (ICR) mice over one month after injection of **2**/**4**~14~, **2**/**3** and PBS ([Figure 6](#pharmaceutics-11-00042-f006){ref-type="fig"}b). It was concluded that mixed micelles **2**/**4**~14~ can serve as a bio-compatible MRI contrast agent similar to **2**/**3**.

Finally, the in vivo MRI experiment using **2**/**4**~14~ was performed for healthy ICR mice. Bright MRI contrast enhancement was observed in the liver in both coronal and sagittal planes over 1 h with high reproducibility ([Figure 7](#pharmaceutics-11-00042-f007){ref-type="fig"}). This result reveals that the magnetic mixed micelle **2**/**4**~14~ is effective as an in vivo *T*~1~-weighted MRI contrast agent. The prolonged MRI enhancement observed for **2**/**4**~14~ is attributed to the high resistance to reducing agents as described above.

3. Conclusions {#sec3-pharmaceutics-11-00042}
==============

We prepared highly robust and biocompatible metal-free magnetic mixed micelles which are composed of non-ionic surfactant **2** and hydrophobic nitroxide radical **4**~n~ in PBS. The time-course stability and in vitro MRI contrast ability of the mixed micelles was found to depend on the length (*n*) of the alkyl chain in the nitroxide radicals. In addition, the mixed micelle **2**/**4**~14~ showed a considerable reduction resistance to a large excess of ascorbic acid, little toxicity, and sufficient contrast enhancement in the *T*~1~-weighted MRI in vivo. Such highly biocompatible magnetic mixed micelles composed of nitroxide radicals bearing a [d]{.smallcaps}-glucosamine unit are expected to be utilized as a low-molecular-weight cancer targeted MRI contrast agent in line with the theranostic applications of micelles, which have recently been attracting increasing interest \[[@B37-pharmaceutics-11-00042],[@B38-pharmaceutics-11-00042],[@B39-pharmaceutics-11-00042]\].

Tween 80 was kindly supplied by DKS Co. Ltd. The MRI experiments of this work were performed in the Division for Small Animal MR, Medical Research Support Center, Graduate School of Medicine, Kyoto University, Japan.

The following are available online at <http://www.mdpi.com/1999-4923/11/1/42/s1>, Scheme S1: Synthesis of **7**~n~ (*n* = 14, 16, and 18); Scheme S2: Synthesis of **4**~n~ (*n* = 14, 16, and 18); Figure S1: FT-IR spectra (KBr) of (**a**) **4**~14~ (**b**) **4**~16~ and (**c**) **4**~18~; Figure S2: HPLC charts of (**a**) **4**~14~, (**b**) **4**~16~, and (**c**) **4**~18~; Figure S3: Representative EPR spectra of **2**/**4**~14~ (a molar ratio of 1:0.01) and the results of their computer simulation at high temperatures; Table S1: Rotation diffusion coefficients and the angles determining the position of the main rotation axis in *g*-tensor frame for radical **4**~14~ in **2**/**4**~14~ (a molar ratio of 1:0.01).

###### 

Click here for additional data file.
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![Molecular structures of non-ionic surfactants Brij 58 (**1**) and Tween 80 (**2**), and nitroxide radicals **3** and **4**~n~ (*n* = 14, 16, and 18). Compounds **4**~n~ are a ca. 1:1 mixture of [d]{.smallcaps}--(*R*,*R*) and [d]{.smallcaps}--(*S*,*S*) diastereomers, see the [Supporting Information](#app1-pharmaceutics-11-00042){ref-type="app"} for the synthesis and characterization.](pharmaceutics-11-00042-g001){#pharmaceutics-11-00042-f001}

![Mean diameters of mixed micelles **2**/**4**~n~ (*n* = 14, 16, and 18) determined by DLS at 25 °C in PBS (black solid line: **2**/**4**~14~ just after preparation, red solid line: **2**/**4**~16~ just after preparation, blue solid line: **2**/**4**~18~ just after preparation, red dashed line: **2**/**4**~16~ after 6 days, blue dashed line: **2**/**4**~18~ after 6 days). See the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"} for experimental details.](pharmaceutics-11-00042-g002){#pharmaceutics-11-00042-f002}

![(**a**) (A--D) *T*~1~-weighted MRI phantom images of **2**/**4**~14~ (**4**~14~: 1.2 to 10 mM), (E--H) **2**/**4**~16~ (**4**~16~: 1.2 to 10 mM) and (I--L) **2**/**4**~18~ (**4**~18~: 1.2 to 10 mM) in PBS, and control PBS at 7.0 T and 25 °C. (**b**) Plots of *T*~1~^−1^ vs concentrations of **2**/**4**~14~ (solid line), **2**/**4**~16~ (dashed line) and **2**/**4**~18~ (dashed and dotted line) at 1.2, 2.5, 5.0, 10 mM for each component. The *r*~1~ was determined from the slope of each line. See the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"} for experimental details.](pharmaceutics-11-00042-g003){#pharmaceutics-11-00042-f003}

![Temperature dependence of rotation diffusion coefficient *D~z~* of **4**~14~ in **2**/**4**~14~ and **3** in **2**/**3**. The data of **2**/**3** was cited from reference 19. See the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"} for experimental details of **2**/**4**~14~.](pharmaceutics-11-00042-g004){#pharmaceutics-11-00042-f004}

![(**a**) Time-course of EPR spectra and (**b**) the reduction resistance of **4**~14~ in **2**/**4**~14~ to a large excess of ascorbic acid (20 equiv based on **4**~14~) in PBS at 25 °C. The normalized signal intensity decay was evaluated by a double-integration method. See the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"} for experimental details.](pharmaceutics-11-00042-g005){#pharmaceutics-11-00042-f005}

![(**a**) In vitro cell viability of **2**/**4**~14~ and **P2** by using the CCK-8 kit after incubation for 24 h at 37 °C under 5% CO~2~ and (**b**) in vivo toxicity of **2**/**4**~14~ for healthy ICR mice weight (three mice for each of **2**/**4**~14~, **2**/**3** and control PBS) as a function of time after injection of 200 μL of mixed micelles (40 mM for each component) in PBS or PBS. See the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"} for experimental details.](pharmaceutics-11-00042-g006){#pharmaceutics-11-00042-f006}

![Time-course of coronal (panels **A**--**D**) and sagittal (panels **E**--**H**) *T*~1~-weighted MR images of an ICR mouse before and after injection of 200 μL of **2**/**4**~14~ (40 mM) in PBS. Distinct contrast enhancement was observed in the liver of the mouse (indicated by white arrows). See the [Supplementary Information](#app1-pharmaceutics-11-00042){ref-type="app"} for experimental details.](pharmaceutics-11-00042-g007){#pharmaceutics-11-00042-f007}

pharmaceutics-11-00042-t001_Table 1

###### 

Mean diameters and colloidal stability of the mixed micelles **2**/**4**~n~ (*n* = 14, 16, and 18) in phosphate-buffered saline (PBS) at 30 °C.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------
  Micelle                                2/4~14~                                2/4~16~                                2/4~18~
  -------------------------------------- -------------------------------------- -------------------------------------- --------------------------------------
  Diameter\                              16 nm ^a^                              13 nm ^a^\                             14 nm ^a^\
  by DLS                                                                        92 nm ^c^                              45 nm ^c^

  Colloidal stability                    Dispersion ^a^\                        Dispersion ^a^\                        Dispersion ^a^\
                                         ![](pharmaceutics-11-00042-i001.jpg)   ![](pharmaceutics-11-00042-i002.jpg)   ![](pharmaceutics-11-00042-i003.jpg)

  Precipitates ^b^\                                                                                                    
  ![](pharmaceutics-11-00042-i004.jpg)                                                                                 

  Dispersion ^d^\                        Dispersion ^c^\                        Dispersion ^c^\                        
  ![](pharmaceutics-11-00042-i005.jpg)   ![](pharmaceutics-11-00042-i006.jpg)   ![](pharmaceutics-11-00042-i007.jpg)   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Immediately after preparation. ^b^ After 24 h of preparation. ^c^ After 6 days of preparation. ^d^ After heating the precipitates.

pharmaceutics-11-00042-t002_Table 2

###### 

The effective activation energy of the rotation diffusion of **4**~14~ in **2**/**4**~14~ and **3** in **2**/**3**.

  Mixed Micelle     *E^a^~z~*/kJmol^−1^
  ----------------- ---------------------
  **2**/**4**~14~   21.1 ± 1.0
  **2**/**3**^a^    18.4 ± 0.4

^a^ Previously reported value \[[@B19-pharmaceutics-11-00042]\].

[^1]: These authors should be addressed as co-first author.
